Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese subjects~* Healthy volunteers with normal body weight, female subject is willing to use a double contraceptive barrier method or an oral hormonal contraceptive during the entire study~Exclusion Criteria:~* Previously participated in any Rotigotine study or participated in another clinical study for an investigational drug~* History of drug or alcohol abuse within the last 2 years~* Suicide attempt or suicidal ideation in the past 6 months~* Transient ischemic attack or stroke within the last 12 months~* Current condition of epilepsy and / or seizures~* History of significant skin hypersensitivity to adhesives or other transdermal products or recently unsolved contact dermatitis~* History or present condition of an atopic or eczematous dermatitis, psoriasis and / or an active skin disease~* Female subject is pregnant or lactating~* Subject has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's wellbeing or ability to participate in this study~* Subject has a QTcB (QT interval corrected for heart rate according to Bazett's formula) interval of ≥ 450 ms for female or ≥ 430 ms for male~* Subject has a relevant hepatic dysfunction (total bilirubin \> 2 mg / dL or alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] greater than 2 times the upper limit of the normal reference range)~* Subject has tested positive for human immunodeficiency virus antibodies (HIV)-1 / 2Ab, hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV-Ab)~* Subject has a positive urine drug screen and / or alcohol breath test on Day 1~* Subject has made a blood donation or had a comparable blood loss (\> 400 mL)~* Subject smokes or has done so within 6 months prior to Eligibility Assessment (EA)~* Subject has a clinically relevant allergy~* Subject is currently taking any medication~* Female subject is currently taking an oral hormonal contraceptive~* Subject has symptomatic orthostatic hypotension~* Subject has a pulse rate at rest less than 45 beats per minute (bpm) or more than 100 bpm~* Subject has a systolic blood pressure (SBP) lower than 100 mmHg or higher than 140 mmHg or diastolic blood pressure (DBP) higher than 90 mmHg~* Subject has a current or a history of clinically relevant motor disturbance, impairment of memory, sleep disturbance or neurodegenerative disease~* Subject has consumed more than 3 cups (more than 450 ml) of caffeinated beverages per day~* Subject's abdomen is thickly covered with hair resulting in difficulties in finding appropriate patch application sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Rotigotine, Period 1 (Type: EXPERIMENTAL): In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
- Rotigotine, Period 2 (Type: EXPERIMENTAL): In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete